Controlled immunocorrection and subsequent activation of bone marrow mononuclear cells improve myocardial function in chronic ischemic cardiac failure
- Authors: Temnov A.A.1, Gureev S.V.1, Onishchenko N.A.1, Shumakov V.I.1
-
Affiliations:
- State Scientific Research Institute of Transplantology and Artificial Organs, Russian Ministry of Рublic Health
- Issue: Vol 2, No 1 (2007)
- Pages: 65-73
- Section: Original Study Articles
- Submitted: 03.02.2023
- Accepted: 03.02.2023
- Published: 15.03.2007
- URL: https://genescells.ru/2313-1829/article/view/183342
- ID: 183342
Cite item
Open Access
Access granted
Abstract
Chronic cardiac failure is accompanied with immune dysregulation which severity predetermines the absence of clinic efficiency of autologous bone marrow stem cells (BMSCs). The effect of two-staged activation of bone marrow stem cells (at first, in vivo, then ex vivo) on left ventricle function promotion in patients with chronic cardiac failure has been studied. Two groups of patients with chronic cardiac failure took part in the investigation. The 1st group patients (control, n=50) underwent cardiopulmonary bypass. To the patients of the 2nd group (n=57) 200 mln autologous mononuclear marrow stem cells were introduced intramyocardially during the cardiopulmonary bypass. In the 2nd group patients the original immune dysregulation severity was assessed by assaying the index of white blood cells stimulation (SI) with a chemoluminescent test. In 16 patients with SI>1 and a moderate alteration of immunoassay favorable effect of BMSCs was predicted; bone marrow stem cells were predicted to produce unfavorable clinic effect in 41 patients with SI <1 and profound alterations of immunoassay. 22 patients with SI <1 had undergone immunocorrecting therapy (stem cells in vivo activation). Mononuclear stem cells of patients (n=38 with SI>1 and n=19 with SI<1) were cultured for 5-7 days (stem cells ex vivo activation). The research demostrated that BMSCs culturing in patients with favorable prognosis led to the changes of immunophenotype of bone marrow such as CD3, CD4, CD8, CD 25 increase. The control examination of the patients 6 months after autologous bone marrow cells introduction revealed that positive dynamics of the left ventricle function and the physical activity index (DASI) occurred in patients with SI>1. Controlled immunocorrection performed before derivation of BMSCs, in combination with their subsequent ex vivo activation promoted reliable improvement of functional characteristics of the left ventricle 6 months after cardiopulmonary bypass in comparison with the controls. For autologous bone marrow stem cells to be effective in patients with chronic cardiac failure two-staged activation of BMSCs should be performed: at first, in vivo with immunocorrectors, then ex vivo while culturing.
Keywords
Full Text
About the authors
A. A. Temnov
State Scientific Research Institute of Transplantology and Artificial Organs, Russian Ministry of Рublic Health
Author for correspondence.
Email: redaktor@celltranspl.ru
Laboratory of stem cells biotechnology
Russian Federation, MoscowS. V. Gureev
State Scientific Research Institute of Transplantology and Artificial Organs, Russian Ministry of Рublic Health
Email: redaktor@celltranspl.ru
Laboratory of stem cells biotechnology
Russian Federation, MoscowN. A. Onishchenko
State Scientific Research Institute of Transplantology and Artificial Organs, Russian Ministry of Рublic Health
Email: redaktor@celltranspl.ru
Laboratory of stem cells biotechnology
Russian Federation, MoscowV. I. Shumakov
State Scientific Research Institute of Transplantology and Artificial Organs, Russian Ministry of Рublic Health
Email: redaktor@celltranspl.ru
Laboratory of stem cells biotechnology
Russian Federation, MoscowReferences
- Patel A.N., Geffner L., Vina R.F. et al. Syrgical treatment for congestive heart failure using autologius adult stem cell transplantation. Heart and lung trans. 2004; 23(№2s): 61.
- Perin E.C., Geng Y.-J., Willerson J.T. Adult stem cell in perspective. Circ. 2003; 107: 935-8.
- Perin E.C.; Dohmann Hans F.R., Borojevic R. et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circ. 2003; 107: 2294-302.
- Gao L.R., Wang Z.G., Zhu Z. M. et al. Effect of Intracoronary Transplantation of Autologous Bone Marrow-Derived Mononuclear Cells on Outcomes of Patients With Refractory Chronic Heart Failure Secondary to Ischemic Cardiomyopathy. Am J. Cardiol. 2006; 98(5): 597-602.
- Kuethe F., Richartz B., Kasper Ch. et al. Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans. Int. J. Cardiology 2005; 100(3): 485-91.
- Rosenzweig A. Cardiac cell therapy—mixed results from mixed cells. N. Engl. J. Med. 2006; 355: 1274-7.
- Kinnaird T., Stabile E., Burnett M.S. et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytikines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 2004; 94: 687-2.
- Stefanie D., Spyridopoulos I., Haendeler J. et al. Statins Enhance Migratory Capacity by Upregulation of the Telomere Repeat-Binding Factor TRF2 in Endothelial Progenitor Cells. Circ. 2004; 110: 3136-42.
- Dimmeler S., Zeiher A.M. Wanted! The best cell for cardiac regeneration. J. Am. Coll. Cardiol. 2004; 44(2): 464-6.
- Kocher A.A., Schuster M.D., Szabolcs M.J. et al. Neovascularisation of ishemic myocardium by human bone-marrow derivated angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 2001; 7: 430-6.
- Dewald O., Zymek P., Winkelmann K. et al. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005; 96: 881-9.
- Thum T., Bauersachs J., Poole-Wilson P.A. et al. The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J. Am. Coll. Cardiol. 2005; 46: 1799-802.
- Minatoguchi S., Takemura G., Chen X.H. et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colonystimulating factor treatment. Circul. 2004; 109: 2572-80.
- Trial J., Rossen R.D., Rubio J., Knowlton A.A. Inflammation and Ischemia: Macrophages Activated by Fibronectin Fragments Enhance the Survival of Injured Cardiac Myocytes. Exp. Biol. Med. 2004; 229(6): 538-45.
- Chazaud B., Sonnet C., Lafuste P. et al. Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth. J. Cell. Biol. 2003; 163: 1133-43.
- Anversa P., Susman M. Molecular Genetic Advances in Cardiovascular Medicine. Circ. 2004; 109: 2832-8.
- Awad O., Dedkov E.I, Chunhua J. et al. Differential Healing Activities of CD34+ and CD14+ Endothelial Cell Progenitors. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 758-64.
- Rota M., LeCapitaine N., Hosoda T. Diabetes Promotes Cardiac Stem Cell Aging and Heart Failure, Which Are Prevented by Deletion of the p66shc Gene. Circ. Res. 2006; 99: 42-52
- Rauscher F.M., Goldschmidt-Clermont P.J., Davis B.H. et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circul. 2003; 108: 457-63.
- Messina E., Giacomello A. Diabetic Cardiomyopathy A “Cardiac Stem Cell Disease” Involving p66Shc, an Attractive Novel Molecular Target for Heart Failure Therapy. Circ. Res. 2006; 99: 1-2.
- Karra R.S., Vemullapalli C., Dong E.E. et al. Stem Cells of Aging Donors -Insufficient Capacity to Repair Causes Progression of Atherosclerosis in the Recipient: Molecular Evidence for Arterial Repair in Atherosclerosis. Proc. Natl. Acad. Sci. USA 2005; 102: 16789-94.
- Karra R., Vemullapalli S., Dong C, Herderick EE, Song X, Slosek K, Nevins JR, West M, Goldschmidt-Clermont PJ, Seo D. Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A. 2005;102:16789 -16794
- Lehrke S., Mazhari R., Durand D.J. et al. Aging Impairs the Beneficial Effect of Granulocyte Colony-Stimulating Factor and Stem Cell Factor on PostMyocardial Infarction Remodeling. Circ. Res. 2006; 99(5): 553-60.
- Schatteman G.C., Ma N. Old Bone Marrow Cells Inhibit Skin Wound Vascularization. Stem Cells 2006; 24(3): 717-21.
- Sata M. Role of Circulating Vascular Progenitors in Angiogenesis, Vascular Healing, and Pulmonary Hypertension. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1008-14.
- Epstein S.E., Stabile E., Kinnaird T. et al. Janus Phenomenon The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis. Circul. 2004; 109: 2826-31.
- Nagashima H., Kawashira-Hirata N., Imamura K. et al. Congestive heart failure after peripheral blood stem cells transplantation, role of cytokines. Jpn. Circ. J. 2000; 64: 382-4.
- Boyle A.J., Schulman S.P., Hare J., Oettgen P. Cardiac Stem Cell Therapy: Need for Optimization of Efficacy and Safety Monitoring. Circul. 2006; 114: 339-52.
- Шумаков В.И., Казаков Е.Н., Онищенко Н.A., Гуреев С.В. Первый клинический опыт использования стволовых клеток костного мозга для восстановления насосной функции сердца. Росс. кардиологический журнал 2003; 5: 42-6.
- Гуреев С.В., Казаков Е.Н., Онищенко Н.А. Трансплантация клеток костного мозга для лечения сердечной недостаточности. Вестник трансплантологии и искусственных органов 2004; 4: 27-34.
- Hasper D., Hummel M., Kleber F.X. Systemic inflammation in patients with heart failure. European Heart J. 1998; 19: 761-5.
- Levine T.B., Levine A.B., Bolenbaugh J., Green P.R. Reversal of heart failure remodeling with age. Am. J. Geriatr. Cardiol. 2002; 11(5): 299-304.
- Бабаева А.Г. Регенерация и система иммуногенеза. М.: Медицина 1985: 256.
- Реброва О.Ю. Статистический анализ медицинских данных. М.: Медиа Сфера 2003:
- Uemura R., Xu M., Ahmad N., Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ. Res. 2006; 98: 1414-21.
Supplementary files
